← Back to Search

Cell Therapy

CLBS201 for Chronic Kidney Disease

Phase 1
Waitlist Available
Research Sponsored by Caladrius Biosciences, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights

Study Summary

This trial will study the effects of an experimental drug in people with kidney disease and type 2 diabetes.

Eligible Conditions
  • Chronic Kidney Disease

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Serious Adverse Events
Secondary outcome measures
Estimated Glomerular Filtration Rate (eGFR)
UACR & UPCR

Trial Design

1Treatment groups
Experimental Treatment
Group I: CLBS201Experimental Treatment1 Intervention
CLBS201 will be administered in an open-label fashion via intra-renal-arterial infusion in 6 subjects followed by 6 months of observation.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
CLBS201
2022
Completed Phase 1
~10

Find a Location

Who is running the clinical trial?

Caladrius Biosciences, Inc.Lead Sponsor
13 Previous Clinical Trials
1,226 Total Patients Enrolled
Lisata Therapeutics, Inc.Lead Sponsor
15 Previous Clinical Trials
1,336 Total Patients Enrolled
William K SietsemaStudy DirectorVice President, Global Regulatory Affairs

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Can patients who are 20 years or older participate in this research?

"The age bracket for patients that are eligible for this study is between 18 to 75 years old."

Answered by AI

Are there any remaining spots available in this trial for new patients?

"Although no longer actively recruiting patients, this study was last updated on October 7th, 2022. The trial was originally posted on December 17th, 2021. There are 1,916 other trials that are actively recruiting patients."

Answered by AI

Are there any significant risks associated with taking CLBS201?

"CLBS201's Phase 1 status indicates that there is very little data currently available regarding its safety and efficacy, so it was given a score of 1."

Answered by AI

Who would be a good candidate to sign up for this clinical trial?

"The prerequisites for enrolment in this clinical study are that the patient has a diagnosed case of chronic kidney disease (CKD) and is between 18 and 75 years old. So far, 6 people have met the qualifications."

Answered by AI

Who else is applying?

What state do they live in?
Texas
California
How old are they?
65+
18 - 65
What site did they apply to?
Amicis Research Center
What portion of applicants met pre-screening criteria?
Did not meet criteria
Recent research and studies
clinicaltrials.govStudy
CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)
2022. "CLBS201 in Patients With Chronic Kidney Disease (CKD) and Type 2 Diabetes Mellitus (T2DM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04990427.
~2 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top